2022Unpublished venueRequires access

The Future of the Pharmaceutical Industry

Jeffrey S. Barrett

Open publisher page 4 citations

Abstract

In the future of healthcare and specifically the pharmaceutical industry, the era of blockbuster drugs that treat large populations will likely wane. This chapter reviews current trends in the pharmaceutical industry, particularly highlighting those that represent shifts in the industry regarding the manner in which they conduct research and development related to changes in healthcare economics. Both a historical context for these changes as well as likely changes in the industry in the short and long term are projected. After more than a decade of cost-cutting, restructuring, transformations, and turnarounds, the pharmaceutical industry would appear to be suffering from change fatigue. Change has been at the forefront of pharmaceutical executives’ minds for a long time, and pressures have been rising steadily. In the pharmaceutical industry, innovation is often best measured by the number of new chemical entity drugs approved by the FDA.

About this research paper

What this paper is about

In the future of healthcare and specifically the pharmaceutical industry, the era of blockbuster drugs that treat large populations will likely wane. This chapter reviews current trends in the pharmaceutical industry, particularly highlighting those that represent shifts in the industry regarding the manner in which they conduct research and development related to changes in healthcare economics. Both a historical context for these changes as well as likely changes in the industry in the short and long term are projected. After more than a decade of cost-cutting, restructuring, transformations, and turnarounds, the pharmaceutical industry would appear to be suffering from change fatigue. Change has been at the forefront of pharmaceutical executives’ minds for a long time, and pressures have been rising steadily. In the pharmaceutical industry, innovation is often best measured by the number of new chemical entity drugs approved by the FDA.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the future of healthcare and specifically the pharmaceutical industry, the era of blockbuster drugs that treat large populations will likely wane. This chapter reviews current trends in the pharmaceutical industry, particularly highlighting those that represent shifts in the industry regarding the manner in which they conduct research and development related to changes in healthcare economics. Both a historical context for these changes as well as likely changes in the industry in the short and long term are projected. After more than a decade of cost-cutting, restructuring, transformations, and turnarounds, the pharmaceutical industry would appear to be suffering from change fatigue. Change has been at the forefront of pharmaceutical executives’ minds for a long time, and pressures have been rising steadily. In the pharmaceutical industry, innovation is often best measured by the number of new chemical entity drugs approved by the FDA.

Key concepts: Pharmaceutical industry, Restructuring, Context (archaeology), Healthcare industry, Business, Drug industry, Health care, Marketing

Related papers

Back to paper searchBrowse research topicsOriginal source
The Future of the Pharmaceutical Industry — Research Paper | ScholarLens